This company has been acquired
Enfusion Past Earnings Performance
Past criteria checks 2/6
Enfusion has been growing earnings at an average annual rate of 21.3%, while the Software industry saw earnings growing at 19.9% annually. Revenues have been growing at an average rate of 21.9% per year. Enfusion's return on equity is 3.9%, and it has net margins of 1.4%.
Key information
21.3%
Earnings growth rate
-156.4%
EPS growth rate
| Software Industry Growth | 17.3% |
| Revenue growth rate | 21.9% |
| Return on equity | 3.9% |
| Net Margin | 1.4% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Recent updates
An Update On The Enfusion Buyout
Jan 29Enfusion: Revenue Growth Should Start To Accelerate
Dec 24Is There An Opportunity With Enfusion, Inc.'s (NYSE:ENFN) 32% Undervaluation?
Nov 23
Why Private Equity Will Buyout Enfusion
Oct 29
Critical Expansion And Diverse Client Base Propel Future Growth And Margin Enhancement
Sep 15 Enfusion's diversification into insurance and banking and its focus on economical front-to-back platform solutions aim to stabilize and grow revenue.Enfusion: Growth Should Accelerate In Coming Quarters
Aug 19Investors Can Find Comfort In Enfusion's (NYSE:ENFN) Earnings Quality
Aug 14Enfusion: Expectations Of Faster Growth And Higher Margins Justify A Buy Rating
Jun 16Is Now An Opportune Moment To Examine Enfusion, Inc. (NYSE:ENFN)?
Mar 13Capital Allocation Trends At Enfusion (NYSE:ENFN) Aren't Ideal
Feb 19Enfusion: Product Is Sticky And Industry Is Huge
Jan 18Calculating The Fair Value Of Enfusion, Inc. (NYSE:ENFN)
Jan 04Investors Appear Satisfied With Enfusion, Inc.'s (NYSE:ENFN) Prospects As Shares Rocket 28%
Dec 02Enfusion: Still Bullish Considering Q3 EBITDA Beat
Nov 08Why Enfusion, Inc. (NYSE:ENFN) Could Be Worth Watching
Oct 31Enfusion Faces Cross-Currents In Investment Management Software Market
Aug 24Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Aug 11Enfusion: Multiple Catalysts
Jun 20Enfusion, Inc.'s (NYSE:ENFN) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 08Revenue & Expenses Breakdown
How Enfusion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 202 | 3 | 104 | 27 |
| 30 Sep 24 | 195 | 3 | 95 | 25 |
| 30 Jun 24 | 188 | 4 | 96 | 24 |
| 31 Mar 24 | 182 | 3 | 93 | 22 |
| 31 Dec 23 | 175 | 6 | 85 | 20 |
| 30 Sep 23 | 169 | 6 | 88 | 19 |
| 30 Jun 23 | 163 | 6 | 82 | 18 |
| 31 Mar 23 | 157 | 3 | 86 | 17 |
| 31 Dec 22 | 150 | -9 | 98 | 17 |
| 30 Sep 22 | 142 | -208 | 245 | 159 |
| 30 Jun 22 | 132 | -207 | 238 | 158 |
| 31 Mar 22 | 121 | -200 | 224 | 156 |
| 31 Dec 21 | 112 | -188 | 202 | 153 |
| 30 Sep 21 | 103 | -1 | 61 | 9 |
| 30 Jun 21 | 93 | 2 | 54 | 8 |
| 31 Mar 21 | 85 | 3 | 49 | 7 |
| 31 Dec 20 | 80 | 4 | 46 | 6 |
| 31 Dec 19 | 59 | 13 | 24 | 4 |
Quality Earnings: ENFN has high quality earnings.
Growing Profit Margin: ENFN's current net profit margins (1.4%) are lower than last year (3.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ENFN has become profitable over the past 5 years, growing earnings by 21.3% per year.
Accelerating Growth: ENFN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ENFN had negative earnings growth (-55.4%) over the past year, making it difficult to compare to the Software industry average (25.4%).
Return on Equity
High ROE: ENFN's Return on Equity (3.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/22 13:00 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enfusion, Inc. is covered by 3 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin McVeigh | Credit Suisse |
| Parth Talsania | Equisights |
| Gabriela Borges | Goldman Sachs |